42. The Microbiome and Multi-Drug Resistant Organisms
Thursday, October 4, 2018: 10:30 AM-11:45 AM
Room: S 206-208

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • review the data on the role the indigenous microbiota can play in resistance to colonization and disease to multi-drug resistant organisms.
  • analyze the evidence that analysis of the microbiome in an individual patient can provide guidance with formulating specific therapies.
  • discuss the impact that therapies that intentionally or unintentionally modify the microbiota can influence susceptibility to infection with MDROs.

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists

Tracks: Trainee, Transplant ID, Investigative ID, Pediatric ID, Epidemiology and Infection Control, Adult ID

Moderators:  Vincent B. Young, MD, PhD, FIDSA, University of Michigan and L. Clifford McDonald, MD, Centers for Disease Control and Prevention

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-204-L01-P


V. B. Young, Vedanta Biosciences: Consultant , Consulting fee . Finch Therapeutics: Consultant , No financial benefit .

L. C. McDonald, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.